C
Cuu Long Pharmaceutical JSC
VN:DCL
Cuu Long Pharmaceutical JSC
VN:DCL
Price:
25 100
VND
-2.14%
Market Cap:
1.8T
VND
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
DCL Alert
Cuu Long Pharmaceutical JSC
25100
-550 (-2.14%)
| 52 Week Range |
24 600
29 850
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Cuu Long Pharmaceutical JSC
Balance Sheet
Balance Sheet Decomposition
Cuu Long Pharmaceutical JSC
Cuu Long Pharmaceutical JSC
| Current Assets | 1.5T |
| Cash & Short-Term Investments | 221.9B |
| Receivables | 788.6B |
| Other Current Assets | 503.3B |
| Non-Current Assets | 900.1B |
| PP&E | 860.4B |
| Intangibles | 23.2B |
| Other Non-Current Assets | 16.5B |
| Current Liabilities | 679.2B |
| Accounts Payable | 124B |
| Accrued Liabilities | 32.7B |
| Short-Term Debt | 373.1B |
| Other Current Liabilities | 149.4B |
| Non-Current Liabilities | 273B |
| Long-Term Debt | 254.5B |
| Other Non-Current Liabilities | 18.6B |
Balance Sheet
Cuu Long Pharmaceutical JSC
Cuu Long Pharmaceutical JSC
Currency: VND
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
18 363
|
13 249
|
11 111
|
19 920
|
22 604
|
14 499
|
41 878
|
41 255
|
52 852
|
23 517
|
|
| Cash |
18 363
|
13 249
|
11 111
|
19 920
|
22 604
|
14 499
|
12 878
|
14 909
|
52 852
|
23 517
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
29 000
|
26 346
|
0
|
0
|
|
| Short-Term Investments |
0
|
200 000
|
206 000
|
224 400
|
640 490
|
838 255
|
877 876
|
655 923
|
248 495
|
204 149
|
|
| Total Receivables |
194 244
|
164 532
|
201 163
|
207 888
|
275 590
|
275 957
|
215 104
|
196 499
|
699 319
|
740 674
|
|
| Accounts Receivables |
183 070
|
149 354
|
184 932
|
175 287
|
208 703
|
194 684
|
162 764
|
147 359
|
194 288
|
266 548
|
|
| Other Receivables |
11 174
|
15 178
|
16 231
|
32 601
|
66 887
|
81 273
|
52 340
|
49 140
|
505 031
|
474 126
|
|
| Inventory |
175 333
|
197 756
|
189 940
|
253 714
|
297 946
|
227 082
|
226 988
|
308 196
|
315 080
|
365 031
|
|
| Other Current Assets |
6 501
|
10 622
|
38 432
|
28 921
|
9 890
|
20 825
|
80 372
|
59 282
|
106 499
|
69 753
|
|
| Total Current Assets |
394 441
|
586 159
|
646 647
|
734 844
|
1 246 520
|
1 376 618
|
1 442 218
|
1 261 155
|
1 422 245
|
1 403 124
|
|
| PP&E Net |
175 183
|
165 008
|
157 626
|
365 276
|
411 592
|
302 607
|
325 499
|
491 030
|
649 459
|
834 368
|
|
| PP&E Gross |
175 183
|
165 008
|
157 626
|
365 276
|
411 592
|
302 607
|
325 499
|
491 030
|
649 459
|
834 368
|
|
| Accumulated Depreciation |
261 875
|
279 346
|
298 860
|
459 504
|
495 858
|
370 136
|
395 160
|
429 218
|
452 753
|
489 444
|
|
| Intangible Assets |
17 524
|
20 474
|
21 394
|
26 236
|
28 422
|
21 474
|
21 366
|
21 151
|
20 984
|
23 316
|
|
| Goodwill |
0
|
0
|
0
|
38 878
|
31 156
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
120
|
0
|
18 952
|
2
|
375
|
375
|
375
|
855
|
3 502
|
|
| Long-Term Investments |
0
|
0
|
10 000
|
30 000
|
0
|
1 000
|
1 000
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
6 206
|
8 862
|
9 726
|
6 971
|
13 238
|
10 398
|
9 949
|
7 318
|
11 781
|
13 150
|
|
| Other Assets |
0
|
0
|
0
|
38 878
|
31 156
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
593 354
N/A
|
780 624
+32%
|
845 392
+8%
|
1 221 156
+44%
|
1 730 929
+42%
|
1 712 471
-1%
|
1 800 407
+5%
|
1 781 028
-1%
|
2 105 323
+18%
|
2 277 460
+8%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
42 603
|
31 227
|
24 376
|
69 777
|
49 846
|
40 535
|
26 721
|
31 117
|
36 751
|
66 129
|
|
| Accrued Liabilities |
13 930
|
19 448
|
18 940
|
28 481
|
34 146
|
27 947
|
32 309
|
29 716
|
50 040
|
44 914
|
|
| Short-Term Debt |
0
|
144 620
|
116 142
|
0
|
209 190
|
218 796
|
240 662
|
361 270
|
288 008
|
349 732
|
|
| Current Portion of Long-Term Debt |
219 456
|
1 184
|
0
|
138 259
|
44 094
|
21 316
|
21 316
|
32 466
|
65 986
|
72 404
|
|
| Other Current Liabilities |
6 849
|
9 934
|
25 949
|
32 036
|
4 340
|
18 053
|
22 573
|
198 228
|
113 283
|
84 895
|
|
| Total Current Liabilities |
282 837
|
206 412
|
185 408
|
268 554
|
341 615
|
326 647
|
343 581
|
652 797
|
554 068
|
618 075
|
|
| Long-Term Debt |
0
|
2 367
|
0
|
158 065
|
581 843
|
499 834
|
485 617
|
106 561
|
159 598
|
208 593
|
|
| Minority Interest |
0
|
1 222
|
1 222
|
56 596
|
56 584
|
47 516
|
69 473
|
51 372
|
18 024
|
18 441
|
|
| Other Liabilities |
4 893
|
4 346
|
3 338
|
2 768
|
2 344
|
1 568
|
214
|
0
|
0
|
0
|
|
| Total Liabilities |
287 730
N/A
|
211 903
-26%
|
187 523
-12%
|
485 983
+159%
|
982 386
+102%
|
875 565
-11%
|
898 885
+3%
|
810 730
-10%
|
731 690
-10%
|
845 109
+16%
|
|
| Equity | |||||||||||
| Common Stock |
99 137
|
201 190
|
563 328
|
568 328
|
568 328
|
568 328
|
568 328
|
588 328
|
730 410
|
730 410
|
|
| Retained Earnings |
31 727
|
91 570
|
94 521
|
166 825
|
148 729
|
237 093
|
301 709
|
374 714
|
422 844
|
481 561
|
|
| Additional Paid In Capital |
110 087
|
211 289
|
0
|
0
|
0
|
0
|
0
|
7 236
|
220 359
|
220 359
|
|
| Other Equity |
64 672
|
64 672
|
20
|
20
|
31 486
|
31 486
|
31 486
|
20
|
20
|
20
|
|
| Total Equity |
305 623
N/A
|
568 721
+86%
|
657 869
+16%
|
735 173
+12%
|
748 543
+2%
|
836 906
+12%
|
901 522
+8%
|
970 298
+8%
|
1 373 633
+42%
|
1 432 350
+4%
|
|
| Total Liabilities & Equity |
593 354
N/A
|
780 624
+32%
|
845 392
+8%
|
1 221 156
+44%
|
1 730 929
+42%
|
1 712 471
-1%
|
1 800 407
+5%
|
1 781 028
-1%
|
2 105 323
+18%
|
2 277 460
+8%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
37
|
56
|
56
|
57
|
57
|
57
|
57
|
57
|
73
|
73
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
